INS and metabolic syndrome: The activation of inflammatory signaling pathways, such as the nuclear factor kappa B (NF-κB) pathway, inhibits insulin signaling in target tissues such as the liver, skeletal muscle and adipose tissue, resulting in an increase in glycemia and dyslipidemia [16].